The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Headline
The AHA today voiced support for the Recovering Excessive Funds for Unused and Needless Drugs Act (S. 551), legislation that would incentivize manufacturers to…
Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…
Headline
Idaho Gov. Brad Little this week signed legislation adding work requirements to the state’s plan to expand Medicaid coverage to low-income adults.
Headline
Sen. Bernie Sanders, I-Vt., and 14 of his Democratic colleagues today introduced the Medicare for All Act of 2019, legislation that would create a national…
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
Reps. Earl Blumenauer, D-Ore., and Markwayne Mullin, R-Okla., yesterday reintroduced  the Overdose Prevention and Patient Safety Act (H.R. 2062), AHA-supported…